Stereotactic versus whole-brain radiotherapy combined with immunotherapy in driver gene–negative NSCLC with brain metastases: a real-world IPTW analysis - Takeaways - MDSpire

Stereotactic versus whole-brain radiotherapy combined with immunotherapy in driver gene–negative NSCLC with brain metastases: a real-world IPTW analysis

  • By

  • Erha Munai

  • Lisi Sun

  • Amu Jike

  • Dan Tao

  • Nan Li

  • Jiang He

  • Yu He

  • Liang Du

  • Wei Zhou

  • Yongzhong Wu

  • Dingyi Yang

  • June 22, 2026

  • 0 min

Share

  • 1

    This study compares the efficacy and safety of WBRT plus immunotherapy versus SRT plus immunotherapy in driver-gene-negative NSCLC patients with brain metastases.

  • 2

    SRT plus immunotherapy demonstrated significantly longer median overall survival (29.3 months) compared to WBRT plus immunotherapy (19.9 months, P = 0.034).

  • 3

    Intracranial progression-free survival was also superior in the SRT plus immunotherapy group (14.7 months) compared to the WBRT plus immunotherapy group (9.4 months, P = 0.038).

  • 4

    The SRT plus immunotherapy group achieved higher intracranial objective response rates (78.6%) and disease control rates (95.0%) than the WBRT plus immunotherapy group.

  • 5

    SRT plus immunotherapy resulted in a lower incidence of radiation-induced brain injury (3.75%) compared to WBRT plus immunotherapy (10.26%).

Original Source(s)

Stereotactic versus whole-brain radiotherapy combined with immunotherapy in driver gene–negative NSCLC with brain metastases: a real-world IPTW analysis

  • by Erha Munai, Lisi Sun, Amu Jike, Dan Tao, Nan Li, Jiang He, Yu He, Liang Du, Wei Zhou, Yongzhong Wu, Dingyi Yang

  • June 22, 2026

Related Content

Virtual Staining and the Next Era of Pathology

How AI enables scalable biomarker analysis that preserves tissue samples, addressing some of the most persistent bottlenecks in clinical care and research

Case Report: Exchange transfusion for hemolytic anemia and acute kidney injury associated with hepatic arterial infusion chemotherapy with raltitrexed and oxaliplatin in a patient with hepatocellular carcinoma

From ribosomopathies to therapeutic targets: ribosomal alterations in pediatric leukemogenesis and tumorigenesis